Albiglutide (Tanzeum): Manufacturer: GlaxoSmithKline, Wilmington, Delaware. Date of Approval: April 15, 2014. Indication: Albiglutide is indicated for subcutaneous once-weekly injection to improve glycemic control, along with diet and exercise, in adults with type-2 diabetes mellitus. Biological Class: Albiglutide is a dipeptidyl peptidase-4 (DPP4)-resistant glucagon-like peptide-1(GLP-1) dimer fused to human albumin. It is a GLP-1 agonist that helps to enhance the body's natural insulin production in patients with type-2 diabetes.
展开▼
